Selling a Home Health Agency to Private Equity: A 2026 Owner’s Guide
In May 2026, Kinderhook Industries took Enhabit Home Health and Hospice private for roughly $1.1 billion, a deal that valued the company at about 10.2 times EBITDA on around $108 million of EBITDA and $1.06 billion of revenue. For most owners reading this, that headline raises a simpler and more personal question: if a national platform clears 10x, what would a private equity buyer pay for my agency, and what would I have to clean up first? This guide walks through how selling a home health agency to private equity actually works in 2026, what financial buyers underwrite, the multiples in play, and how to prepare so you negotiate from a position of strength.
As of June 2026, the market is active but selective. The Q1 2026 Home-Based Care M&A Report from Mertz Taggart counted 22 closed transactions across home-based care, with home health posting 6 deals (one platform and five sponsor-backed add-ons), the strongest home health quarter in over a year. Capital is available and private equity has dry powder to deploy. What has changed is the underwriting. Buyers now reward clean books, durable census, and diversified payers, and they discount owner dependence, payer concentration, and anything that looks like a compliance risk.
Why is private equity buying home health agencies in 2026?
Private equity is buying home health agencies because the sector pairs durable, demographically driven demand with a fragmented supply of agencies that can be combined into larger, more efficient platforms. An aging population, a clear cost advantage for care delivered at home, and recurring referral-based revenue make home health attractive to financial buyers who want predictable cash flow and a long runway for add-on acquisitions. The Enhabit transaction and the Q1 2026 deal count both point the same direction: sponsors are rotating capital back into post-acute care.
Most of that activity is roll-up activity. A sponsor acquires a larger “platform” agency, then buys smaller agencies as “add-ons” and folds them into shared clinical, billing, human resources, and compliance infrastructure. That structure explains why scale is rewarded so heavily, and why a small agency is usually valued as a tuck-in rather than as a standalone prize. Understanding where your agency sits on that spectrum is the first step in any conversation with a private equity buyer.
What do private equity buyers look for in a home health agency?
Private equity buyers look for defensible, transferable cash flow: diversified referral sources, a stable census, a balanced payer mix, dependable staffing, clean compliance, and EBITDA that survives third-party scrutiny. In 2026 the bar is higher than it was during the 2021 peak. According to the law firm Arnall Golden Gregory, buyers have cut their tolerance for EBITDA add-backs from roughly 20% of EBITDA to a more constrained 12 to 15%, which means owners can no longer inflate earnings with aggressive adjustments and expect a buyer to pay on them.
Eight attributes carry the most weight when a financial buyer evaluates a home health agency:
- Diversified, transferable referrals. Referrals spread across hospitals, physician groups, and facilities, not tied to the owner’s personal relationships.
- Durable census and length of stay. Stable episodic volume and predictable patient counts month to month.
- Balanced payer mix. A spread across traditional Medicare, Medicaid, and private or Medicare Advantage, with Medicare Advantage exposure understood and priced.
- Staffing capacity. Strong clinician retention and low reliance on expensive contract labor, so the agency can staff the growth a buyer is paying for.
- Compliance and billing cleanliness. A clean survey history, no open audits, and documentation that holds up.
- Technology enablement. A modern EMR, scheduling, and billing stack that signals the agency can scale.
- Defensible EBITDA. Earnings supported by a Quality of Earnings file and reasonable, well-documented add-backs.
- Management depth. A team that runs the agency day to day, so value does not walk out the door with the founder.
The table below shows how these drivers move your multiple in opposite directions. Buyers do not pay for hype. They pay for proof, and each row is a place where proof either exists in your records or does not.
| Value driver | Raises your multiple | Lowers your multiple |
|---|---|---|
| Referral sources | Diversified and contracted; transferable to a new owner | Concentrated; tied to the owner’s personal relationships |
| Payer mix | Balanced across Medicare, Medicaid, private and MA | Heavy single-payer or heavy Medicare Advantage concentration |
| Staffing | High clinician retention, low contract-labor use | High turnover, persistent agency or contract staffing |
| Compliance | Clean surveys, no open audits, organized documentation | Survey deficiencies, billing audits, ADR backlogs |
| Earnings quality | Defensible EBITDA backed by a QoE report | Aggressive add-backs with no support |
| Owner role | Management team runs operations without the owner | Owner is the agency; nothing runs without them |
| Scale | Multi-branch, multi-state, platform potential | Single small location, tuck-in only |
What multiple will private equity pay for a home health agency?
As of June 2026, private equity typically pays in the range of 6.0x to 8.0x adjusted EBITDA for regional and add-on home health agencies, and 8.0x to 12.0x for platform-tier operators, though every range depends on payer mix, geographic footprint, staff retention, compliance history, and referral durability. Independent advisory data from FOCUS and CT Acquisitions puts mid-market multi-location agencies in the 6.0x to 8.0x band, with scaled multi-state certified platforms carrying diversified payers and high CMS star ratings reaching 9.0x to 12.0x and above. Platforms generally command roughly 3 to 5 turns more than tuck-in add-ons.
Payer mix is the swing factor inside those bands. Benchmark reports from Hendon Partners and Breakwater M&A indicate that a diversified book, for example roughly 40% Medicare, 30% Medicaid, and 30% private or Medicare Advantage, can lift the multiple by about 1 to 2 turns versus a concentrated mix. A heavy Medicare Advantage concentration works the other way, because Medicare Advantage plans often reimburse below traditional Medicare and compress margins. The reimbursement backdrop matters too: CMS finalized a CY2026 home health rule with a 1.3% aggregate payment cut, about $220 million versus 2025, including a temporary 3.0% adjustment, and buyers price that into go-forward earnings.
A short caution on multiples: a number you read in a report is not an offer. Two agencies with identical EBITDA can be 3 turns apart on price because one has clean diligence and a transferable referral base and the other does not. The point of preparation is to move your own agency up its band, not to chase a headline figure from a billion-dollar platform deal.
What is the difference between a platform and an add-on deal?
A platform deal is a private equity firm’s first, anchor acquisition in home health, valued for its scale and infrastructure, while an add-on (or tuck-in) is a smaller agency bought to fold into an existing platform. The distinction drives both your price and your role after closing. Platform sellers often command premium multiples and may stay on to lead a larger entity. Add-on sellers typically receive a lower multiple, integrate into the buyer’s systems, and may have a shorter transition. Knowing which one you are helps you set realistic expectations before you ever take a meeting.
| Dimension | Platform deal | Add-on (tuck-in) deal |
|---|---|---|
| Typical size | Larger, multi-branch or multi-state | Smaller, single or few locations |
| Typical multiple | 8.0x to 12.0x+ EBITDA | 6.0x to 8.0x EBITDA |
| Buyer’s goal | Anchor to build on and acquire under | Volume and density for an existing platform |
| Owner’s role after | Often retained to lead the platform | Integrated; shorter transition common |
| Infrastructure valued | Management depth, systems, compliance | Census, referrals, local market share |
| Deal structure | May include meaningful equity rollover | More often majority or full cash |
How does private equity diligence a home health agency?
Private equity diligence on a home health agency centers on a Quality of Earnings review, working-capital normalization, compliance and billing testing, payer-mix analysis, and a hard look at staffing and referral durability. In 2026, a third-party Quality of Earnings (QoE) report has become close to mandatory for any seller hoping to reach the top of a valuation band. Buyers use the QoE to confirm that reported EBITDA is real, that add-backs are reasonable, and that the cash flow they are paying for will survive the transition.
Expect diligence to probe five areas in depth. First, earnings quality, where every add-back is tested and the tighter 12 to 15% add-back tolerance is applied. Second, working capital, where the buyer sets a target so neither side is surprised at closing. Third, compliance, including survey history, billing accuracy, and any open audits or additional documentation requests. Fourth, payer mix and reimbursement exposure, especially Medicare Advantage concentration. Fifth, labor, where contract-labor reliance and clinician turnover are recast as both a margin risk and an integration risk. Diligence timelines have stretched, so the cleaner your records, the faster and smoother the process.
How do I prepare my home health agency for a private equity sale?
Preparing a home health agency for a private equity sale means organizing your financials, diversifying referrals and payers, stabilizing staffing, closing compliance gaps, and reducing the agency’s dependence on you, ideally 12 to 24 months before you go to market. Most owners come to an advisor 6 to 9 months later than they should. There is usually still time to fix the things that matter, but the earlier you start, the more value you protect. The steps below are the same ones a buyer will grade you against.
Eight steps to prepare for a private equity sale
- Get your books buyer-ready. Move to accrual-based, monthly financials and document every add-back so a QoE review can confirm them.
- Commission a sell-side Quality of Earnings. Find and fix the issues a buyer’s QoE would flag before they cost you negotiating room at the table.
- Diversify referrals. Broaden referral sources and put them on contracts where possible so they transfer to a new owner.
- Balance your payer mix. Understand your Medicare Advantage exposure and rebalance toward a diversified book where you can.
- Stabilize staffing. Reduce contract-labor reliance, improve clinician retention, and document your recruiting engine.
- Close compliance gaps. Resolve survey deficiencies, clean up billing, and organize documentation for fast review.
- Build management depth. Delegate operations so the agency runs without you, which removes the single biggest discount on small-agency value.
- Get a confidential valuation and run a process. Know your range before you negotiate, and let an advisor create competition among qualified buyers.
What is your home health agency worth to a private equity buyer? Start with a confidential, no-obligation estimate using the ValueMyBusiness valuation calculator, then book a private conversation with the healthcare M&A team at Vallexa Advisors. We work on success-based fees, so our incentives are aligned with your outcome.
Should I sell my home health agency to private equity now or wait?
Whether to sell now or wait depends on your agency’s readiness, your personal timeline, and where the market sits, not on any single headline, and the honest answer for many owners is that preparation should start now even if the sale does not. The 2026 market favors prepared sellers: capital is available, platforms are actively acquiring, and well-run agencies are clearing healthy multiples. At the same time, reimbursement pressure from the CMS CY2026 rule and tighter diligence mean unprepared agencies are getting repriced. If your books, referrals, payers, and staffing are in order, a strong buyer market is a good reason to explore your options. If they are not, the 12 to 24 months you spend fixing them is rarely wasted.
Waiting has real trade-offs in both directions. Wait too long and you risk a reimbursement change, a failed survey, or a key referral source moving, any of which can erase value quickly. Move before you are ready and you negotiate from weakness. The way through is to get a current valuation, understand your gaps, and make the decision with numbers in front of you rather than on instinct. For a deeper look at timing and sequencing, see our overview of the seven steps to selling.
Is selling to private equity right for every owner?
Selling to private equity is not the right path for every owner, and a good advisor will tell you when a strategic buyer, a recapitalization, or staying independent is the better fit. Private equity tends to suit owners who want meaningful liquidity now, are comfortable with new ownership and reporting discipline, and may want to roll equity into a larger platform for a “second bite” at a future sale. A strategic buyer, often a larger operator, may pay for synergies and offer a cleaner exit if you want to step away entirely. A recapitalization lets you take chips off the table while keeping a stake and a role.
Whatever the path, confidentiality protects your value. Staff, referral sources, and competitors should not learn you are exploring a sale until you choose to tell them. A disciplined process, run under non-disclosure agreements with qualified buyers only, keeps your operation stable while you evaluate offers. That is the core of how we run an engagement, and it is why owners often start with a quiet valuation long before they commit to anything. Anonymous buyer demand can be tested through platforms like Exits.ai, and timing and succession questions are worth working through with ExitStrategies.com.
Frequently asked questions
How long does it take to sell a home health agency to private equity?
A typical home health sale to private equity runs about 6 to 9 months from engagement to closing, though preparation before that can add 12 to 24 months. Tighter 2026 diligence and longer buyer timelines mean clean records shorten the process and messy ones extend it.
Will I have to stay on after selling to private equity?
It depends on the deal. Platform sellers are often retained to lead the larger entity, while add-on sellers usually go through a shorter transition. Many private equity deals include an equity rollover that keeps the owner financially involved through a future sale.
What is a Quality of Earnings report and do I need one?
A Quality of Earnings (QoE) report is a third-party analysis that verifies your true, recurring EBITDA and tests your add-backs. As of 2026, buyers will not pay top-of-band without one, so a sell-side QoE before going to market is one of the highest-return steps an owner can take.
How does payer mix affect what private equity will pay?
Payer mix is one of the largest single drivers of a home health multiple. A diversified book can lift the multiple by roughly 1 to 2 turns, while heavy Medicare Advantage concentration pressures margins and the price because those plans often reimburse below traditional Medicare.
Is my agency too small for private equity?
Smaller agencies are usually acquired as add-ons rather than platforms, but that does not mean they are unsellable. A clean, well-run small agency with diversified referrals and payers can be an attractive tuck-in for a sponsor building density in your market.
Will selling to private equity affect patient care or my staff?
Buyers value durable census and staff retention, so most aim to keep care and clinical teams stable, since that is what they paid for. Deal terms can address staff treatment and transition, which is one reason to negotiate with experienced advisory support.
How do I keep a sale confidential?
Confidentiality is maintained by running a structured process under non-disclosure agreements, disclosing your identity only to qualified, vetted buyers, and controlling what information is shared and when. This protects your relationships with staff, referral sources, and competitors while you evaluate offers.
About the author
Jason Atty is the founder of Vallexa Advisors, a healthcare-only M&A advisory firm that helps home health, hospice, and home care owners understand value, prepare intelligently, and run confidential sale processes that attract qualified buyers. Vallexa works on 100% success-based fees, with a healthcare-only focus, a confidentiality-first approach, and a nationwide buyer network. The firm advises owners across the home-based care spectrum on valuation, preparation, and exit strategy. As of June 2026, Vallexa continues to track home health M&A activity, CMS reimbursement changes, and private equity buyer demand to help owners time and structure their decisions.
Considering a sale, or just want to know your number? Start a confidential, no-obligation conversation with Vallexa Advisors, run a quick estimate with the valuation calculator, and ask us for the home health pre-sale readiness checklist so you can see exactly where your agency stands before any buyer does.
Related resources
- Home health M&A advisory
- Business valuation calculator
- The 7 steps to selling
- Anonymous buyer mandates (Exits.ai)
- Exit and succession planning
Educational only. Not legal, financial, or tax advice. Healthcare M&A outcomes depend on specific facts, payer mix, market conditions, and regulatory context. Speak with qualified counsel before acting on anything in this document.
Sources: CMS CY2026 Home Health PPS Final Rule fact sheet (CMS, 2025); Mertz Taggart Q1 2026 Home-Based Care M&A Report (2026); Arnall Golden Gregory, Home Health & Hospice M&A in 2026 (2026); Healthcare Dive, Enhabit and Kinderhook $1.1B (2026); FOCUS and Hendon Partners 2026 home health multiple benchmarks (2026).
/
Key Takeaways
- In 2026, private equity buys home health agencies for their stable demand and growth potential, focusing on clean financials and diversified referrals.
- Investors typically pay 6.0x to 8.0x EBITDA for regional agencies, while platforms fetch 8.0x to 12.0x, depending on factors like payer mix and compliance history.
- Private equity buyers prefer defensible cash flow, diversified referrals, and stable staffing; thus, agencies must prepare to meet these standards before selling.
- The diligence process now requires a Quality of Earnings report to validate cash flow and support earnings, making preparation essential for sellers.
- Ultimately, deciding when to sell hinges on agency readiness and market conditions; preparation can significantly maximize agency value.
Estimated reading time: 14 minutes
